280E Updates: Rescheduling, Amending Returns, and Why Timing Matters - Sign up for our free webinar now!
280E Updates: Rescheduling, Amending Returns, and Why Timing Matters - Sign up for our free webinar now!
Ask the Experts | Cannabis Business Times

Sign in or create a free Cannabis Business Times account to continue reading

Continue to Site »
Site will load in 15 seconds

Ask the Experts

We asked 13 specialists to provide insights into essential cannabis-production topics to help cultivators enhance their businesses.

July 14, 2021
Adobe Stock 317312852 De
prostock-studio | Adobe Stock
Recommended
280E Updates: Rescheduling, Amending Returns, and Why Timing Matters - Sign up for our free webinar!
Sponsored
280E Updates: Rescheduling, Amending Returns, and Why Timing Matters - Sign up for our free webinar!
Pleo Pharma Logo
PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder
Best Cannabis Companies 2027 Call For Entries Top Story Image With Black Border
Best Cannabis Companies to Work For
Cannara VP of Production and Experimentation Issam Ben Moussa
How to Turn LED Lighting Into a Strategic Cultivation Tool
More in Home
Sens. Ted Budd and Pete Ricketts' Hemp Product Ban Amendment
NMAI Letter RE: Final Determination Regarding Idaho Medical Cannabis Act Initiative Petition
What Is Certified Human-Composed Creation and Why Is It Important?
Massachusetts State Ballot Law Commission Ruling on Cannabis Petition - July 21, 2026
NDASA and MMJ Response to DOJ's Schedule III Stay Opposition - July 16, 2026
Image Distillate
Image Trimmer Test
Massachusetts State Ballot Law Commission Notice of Hearing 26-06 - July 2026
Kevin Gilnack Objection to Massachusetts Cannabis Petition Filed With State Ballot Law Commission -- July 8, 2026
Massachusetts Elections Division Letter to Coalition for a Healthy Massachusetts - July 9, 2026
DOJ Response Opposing NDASA/MMJ's Motion to Stay Schedule III Order
PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder
The trial of PP-01 (CAN-004) advances an investigational, once-daily therapy for withdrawal symptoms in patients with cannabis use disorder.
Pleo Pharma Logo
Page 1 of 10
Next Page